Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis

Introduction The available oral anti-Xa agents are routinely used for the management of thrombotic disorders. A molecularly modified recombinant coagulation FXa, also known as Andexanet Alfa (AA), that has been developed as an antidote to neutralize the bleeding effects of oral FXa inhibitors, such...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Siddharth Mehrotra, Debra Hoppensteadt PhD, Walter Jeske PhD, Fakiha Siddiqui BS, Omer Iqbal MD, Alfonso Tafur MD, Bruce Lewis MD, Mark Jaradeh BS, Bulent Kantarcioglu MD, Jawed Fareed PhD
Format:	Artigo
Język:	Inglês
Wydane:	SAGE Publishing 2022-12-01
Seria:	Clinical and Applied Thrombosis/Hemostasis
Dostęp online:	https://doi.org/10.1177/10760296221138297
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!